Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc.

ESPRNYSE / NASDAQHealthcareSmall cap

$3.18$0.00 (0.0%)

Last close · Data as of Jul 14, 2026

Market cap
$805.8M
EV / EBITDA
13.9x
Revenue
$403.1M
Net margin
-5.6%
ROCE
-121.5%

Hidden because the last close is more than three trading days older than the latest prices of its class.

Esperion Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 14 Jul 2026 close.

1M
Stale
3M
Stale
6M
Stale
1Y
Stale
5Y
Stale
  • Hidden because the last close is more than three trading days older than the latest prices of its class.

52-week range

Day change $0.00 (0.0%) from $3.18 to $3.18 · Last close Jul 14, 2026

Best weekday to invest, historically

The same weekly amount in ESPR, bought on each weekday since 2021.

News & filings

What Esperion Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths (1)

  • Operating margin of 15.0% against a peer median of 0.8%.
  • Prices are as of 14 Jul 2026; price-based points are paused until newer prices arrive.
  • The stored ratios (as of 11 Jun 2026) describe a profitable period while fiscal 2025 shows a net loss: the two cover different periods, so the ratio points are not shown.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.

Prices to the 14 Jul 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States.

Read moreShow less

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Sector
Healthcare
Shares outstanding
245.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$805.8M
EV / EBITDA
13.9x
EV / Sales
2.2x
P/S
2.0x
52-week high
$4.08
52-week low
$1.12

Profitability

Operating margin
15.0%
Net margin
-5.6%
EBITDA margin
15.8%
ROE
7.5%
ROCE
-121.5%
ROA
-4.9%
Asset turnover
0.87

Growth

Revenue
$403.1M
Revenue growth, 1Y
21.3%
Revenue CAGR, 3Y
74.8%
Net profit growth, 1Y
-56.2%
Free cash flow
-$13.1M

Solvency

Current ratio
1.54
Debt / Assets
0.54
CFO / Net profit
0.58
Cash / Market cap
20.8%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$403.1M
Cost of revenue$129.2M
Gross profit$273.9M
Operating expenses$213.6M
Research and development$47.9M
Selling, general and administrative$165.8M
Operating income$60.3M
Interest and other-$81.1M
Pretax income-$20.8M
Tax and other$1.8M
Net income-$22.7M

Revenue and net profit

Revenue grew 21.3% in FY2025; net profit is the dashed line.

Esperion Therapeutics, Inc. revenue and net profit by fiscal year
Esperion Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$75.5M-$233.7M
FY2023$116.3M-$209.2M
FY2024$332.3M-$51.7M
FY2025$403.1M-$22.7M

Cash flows

FY2025: -$13.1M from operations, -$13.1M free after investment (dashed).

Esperion Therapeutics, Inc. operating and free cash flow by fiscal year
Esperion Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$174.8M-$174.8M
FY2023-$135.5M-$135.5M
FY2024-$23.7M-$24.0M
FY2025-$13.1M-$13.1M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$403.1M+21.3%1Y
EBITDA
$63.9M+743.8%1Y
Net profit
-$22.7M
Cash from operations
-$13.1M
Free cash flow
-$13.1M
Revenue CAGR, 3Y
74.8%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$403.1M$63.9M-$22.7M-$13.1M7.5%+21.3%-56.2%

Monthly returns

Month-by-month returns of ESPR across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$465.9M
Liabilities$767.9M
Equity-$302.0M
Paid-in capital$1.4B
Retained earnings-$1.6B
Treasury stock$55.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ESPR highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Esperion Therapeutics, Inc. (this company)2.2x

Not shown (no positive earnings and no EV / Sales): ORIC Pharmaceuticals, Inc., LB Pharmaceuticals Inc, Sana Biotechnology, Inc., Replimune Group, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Esperion Therapeutics, Inc.ESPRthis company$805.8M——7.5%13.9x
ORIC Pharmaceuticals, Inc.ORIC$830.2M-6.4x2.2x-33.7%-5.6x
LB Pharmaceuticals IncLBRX$828.8M-32.9x2.8x-8.4%-19.4x
Amphastar Pharmaceuticals, Inc.AMPH$824.5M8.4x1.0x12.4%6.2x
Sana Biotechnology, Inc.SANA$823.7M-3.4x5.1x-151.8%-4.3x
Replimune Group, Inc.REPL$815.0M-3.3x2.0x-59.5%-3.3x
Lumexa Imaging Holdings, Inc.LMRI$791.7M-16.8x1.4x-8.0%12.0x
Eton Pharmaceuticals, Inc.ETON$791.6M-172.1x30.3x-17.6%249.0x
Phathom Pharmaceuticals, Inc.PHAT$786.4M-3.6x-1.8x50.5%-5.7x
Peer median—-5.0x2.1x-13.0%-3.8x

Year-to-date ROI

ESPR since 1 January, against earlier years.

Historical volatility

ESPR's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Esperion Therapeutics, Inc. operating margin by fiscal year
Esperion Therapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY2022-237.8%
FY2023-133.7%
FY202416.4%
FY202515.0%
LineFY2025
Cost of revenueCost Of Revenue$129.2M
Gross profitGross Profit$273.9M
Operating expensesOperating Expense$213.6M
Research and developmentResearch And Development$47.9M
Selling, general and administrativeSelling General And Administration$165.8M
Total expensesTotal Expenses$342.9M
Pretax incomePretax Income-$20.8M

Learn while you research

Academy chapters picked for Esperion Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing21% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →